No Data
Jiangsu Apon Medical Technology (300753.SZ): The subsidiary Pengrui Neuroscience is developing a multimodal ADHD behavioral training system specifically designed for individuals with attention deficit hyperactivity disorder.
On April 22, Gelonghui reported that Jiangsu Apon Medical Technology (300753.SZ) stated on the investor interaction platform that its subsidiary, Pengrui Brain Science, is developing a multimodal ADHD behavioral training system specifically designed for individuals with attention deficit hyperactivity disorder. This system utilizes scientific brainwave monitoring and multimodal intervention training to help children gradually improve hyperactive and attention deficit behaviors, enhancing their concentration. This product has not yet obtained a medical instruments registration certificate, so all investors are advised to make rational decisions, invest cautiously, and pay attention to investment risks.
Aipon Healthcare: 2024 Annual Report Summary
AIPON HEALTHCARE: 2024 ANNUAL REPORT
Jiangsu Apon Medical Technology (300753.SZ) released its 2024 annual performance, with a net income of 10.8007 million yuan, an increase of 30.49%.
Jiangsu Apon Medical Technology (300753.SZ) released its annual report for 2024, and the company's revenue is 0.404 billion yuan...
Jiangsu Apon Medical Technology Co., Ltd.'s (SZSE:300753) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Jiangsu Apon Medical Technology (300753.SZ): The increase in USA tariffs has almost no impact on the company.
On April 8, Gelonghui reported that Jiangsu Apon Medical Technology (300753.SZ) stated on the investor interaction platform that according to the company's 2023 annual report and 2024 semi-annual report disclosure data, the company has no overseas business income. The increase in tariffs in the USA has almost no impact on the company.
Jiangsu Apon Medical Technology Co., Ltd. (SZSE:300753) Not Doing Enough For Some Investors As Its Shares Slump 25%
